Biotech Values

[lax20m]

Everyone on the Ariad board hates her but I find their arguments don't hold water. However with that being said I do think the 3 dollar price target from her is retribution for feeling that she was duped by Harvey. The drug clearly will be successful in the t315i and salvage market. If they can find a way to address the safety issues it might have a chance at second line and there are plenty of other indications that the drug has promise, such as gist. I wouldn't be surprised if iclusig reaches 500m in global sales. Then there is 113. Yes it's a crowded space but it's been quite effective in trials has been very effective with brain mets and is currently getting no consideration in the valuation of the company. 3 bucks per share is a market cap of about half a billion. Maybe a bit more. I don't take into account further dilution options etc but also don't count their current cash in my assessment of their enterprise value. I think she is low and I think she has a bias. Although frankly I don't follow her coverage on other companies closely, if at all so I don't know if her scrutiny of Ariad is consistent with her coverage of other companies.